Abstract: Objective:To examine the clinical value of combining indocyanine green (ICG) fluorescence navigation with blue dye in sen -tinel lymph node biopsy (SLNB) for patients with breast cancer. Methods:A total of 89patients with early- stage breast cancer who met the inclusion criteria were admitted at Shantou Central Hospital, Guangdong from May2013to April2014. In phase one, ICG and blue dye were applied in all 53patients, and then SLNB and axillary lymph node dissection (ALND) were performed based on fluores -cence signal or visual sense of the lymph nodes. In phase two, 36patients with early- stage breast cancer were included. ALND was omitted when sentinel lymph nodes were frozen showing negative result. Rates of detection, accuracy, and false-negative were calcu-lated. Results:A total of 89patients were monitored, of which the total rate of SLNB detection was 96. 6% (86/89). In the validation pe -riod, the rates of detection, accuracy, and false negative were 94. 3% (50/53) 98. 0% (49/50), and 2. 6% (1/38), respectively. In the alter -ative period, the rates of detection reached100 % . Of the196 sentinel lymph nodes, 179 showed fluorescence signal, 142 exhibited blue dying, 54only demonstrated fluorescence signals, and45demonstrated metastasis with five signaling fluorescence. About 24. 7% of patients were diagnosed with SLN metastasis ( 22/89), where SLNB in two patients showed fluorescence signal but without blue dye. No ipsilateral lymph node relapsed were observed during a median follow up of25months.Conclusion: Combination of ICG fluores-cence navigation with blue dye in SLNB is safe for patients with breast cancer.